Patents Assigned to Center for Disease Control and Prevention
-
Publication number: 20130330726Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.Type: ApplicationFiled: February 17, 2012Publication date: December 12, 2013Applicant: Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
-
Patent number: 8603745Abstract: Disclosed are artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular mutation. Also provided are methods of generating such compositions, and methods of their use.Type: GrantFiled: March 11, 2005Date of Patent: December 10, 2013Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention, The Regents of the University of CaliforniaInventors: Wayne W. Grody, Michael R. Jarvis, Ramaswamy K. Iyer, Laurina O. Williams
-
Publication number: 20130321804Abstract: Particles of a flow of aerosol are collected and analyzed by passing them through a housing having an inlet area, an outlet area, and a collection and analysis area. A collection electrode has a tip disposed in the flow path in the collection and analysis area. Particles are collected on the tip of the collection electrode. A microwave pulse is applied to the collection and analysis area such that a plasma is created. Atomic emissions produced during at least part of the microwave step are collected for analysis of the ablated particles.Type: ApplicationFiled: March 14, 2013Publication date: December 5, 2013Applicant: CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Pramod Kulkarni, Philip Efthimion
-
Patent number: 8592146Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.Type: GrantFiled: September 4, 2012Date of Patent: November 26, 2013Assignee: Centers for Disease Control and PreventionInventors: Jeffrey A. Johnson, Walid M. Heneine
-
Publication number: 20130295557Abstract: A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.Type: ApplicationFiled: January 26, 2012Publication date: November 7, 2013Applicant: Centers for Disease Control and PreventionInventors: Jennifer Dolan Thomas, Xin Wang, Cynthia Hatcher, Raydel Anderson, Mary Jordan Theodore, Leonard W. Mayer
-
Patent number: 8573199Abstract: A respiratory mask includes a mask body with a perimeter. The mask has a use position wherein the mask body covers at least the mouth and nose and the perimeter is in contact with the face surrounding at least the mouth and nose. At least one ultrasonic sensor is supported on the mask body in detecting proximity to the perimeter. The ultrasonic sensor is operable to detect ultrasound. The ultrasonic sensor allows leakage around the perimeter of the mask body to be detected.Type: GrantFiled: May 2, 2011Date of Patent: November 5, 2013Assignee: Centers for Disease Control and PreventionInventors: William Porter King, Jonathan Szalajda
-
Patent number: 8575324Abstract: Reagents and assays for detecting HIV-1 groups M and O and optionally HIV-1 group N and SIVcpz are provided. The reagents are nucleic acid primers for the hybridization to, amplification and subsequent detection of HIV-1 groups M, N and O and SIVcpz in a biological sample. The primers are oligonucleotides that selectively hybridize to the highly conserved regions of the env and pol regions of HIV-1. Due to the high sensitivity of the assays, small concentrations of HIV in a biological sample can be detected, allowing diagnosis at an early stage of infection. The assays are qualitative or quantitative and are useful for viral load determinations of HIV-1 groups M, N or O in a patient undergoing treatment for HIV-1 infection. Viral load determinations can be used to monitor the progress of the treatment regimen, the development of drug resistance, and to predict disease progression.Type: GrantFiled: December 27, 2006Date of Patent: November 5, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Renu B. Lal, Danuta Pieniazek, Chunfu Yang
-
Patent number: 8568981Abstract: Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.Type: GrantFiled: July 20, 2012Date of Patent: October 29, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Stephen Lindstrom, Alexander Klimov, Nancy Cox, Lamorris Loftin
-
Publication number: 20130280714Abstract: Processes for the serotype specific detection and identification of one or more Salmonella serotypes are provided. A family of specific primers and probes are provided that allow screening of biological or environmental samples for robust, rapid, and reproducible detection and identification of one or more Salmonella serotypes in the sample.Type: ApplicationFiled: April 26, 2013Publication date: October 24, 2013Applicant: Centers for Disease Control and PreventionInventors: Patricia Fields, John R. McQuiston, Collette Fitzgerald Leaumont
-
Patent number: 8544462Abstract: Aerosol delivery systems and methods for delivering an agent to a patient are described herein. In particular embodiments, an insulated receptacle is connected to a housing and holds a vial of an agent to be delivered to a patient. The vial is located in an inverted position within the receptacle. One or more reusable thermal packs can be located on the inner sides of the receptacle, to maintain a selected temperature surrounding the vial. The agent is administered to a patient by placing a prong into one of the patient's orifices and then activating an aerosol delivery system. Such systems can include jet aerosolization and pneumatic and ultrasonic nebulizers and preferably are portable.Type: GrantFiled: April 27, 2007Date of Patent: October 1, 2013Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Creare IncorporatedInventors: Mark James Papania, James J. Barry, Nabil A. Elkouh, Mark C. Bagley
-
Patent number: 8541221Abstract: Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.Type: GrantFiled: July 1, 2010Date of Patent: September 24, 2013Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Johns Hopkins UniversityInventors: William M. Switzer, Walid Heneine, Thomas M. Folks, Nathan D. Wolfe, Donald S. Burke, Eitel Mpoudi Ngole
-
Patent number: 8530182Abstract: A process of quantifying proteins in a complex mixture is provided. The invention has utility in quantifying proteins in a complex preparation of uni- or multivalent commercial or research vaccine preparations.Type: GrantFiled: December 5, 2008Date of Patent: September 10, 2013Assignee: Centers for Disease Control and PreventionInventors: John R. Barr, Tracie L. Williams, Leah G. Luna, Zhu Guo, Rubin Donis, James L. Pirkle
-
Patent number: 8524247Abstract: Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.Type: GrantFiled: August 20, 2009Date of Patent: September 3, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Xianfu Wu, Charles Rupprecht
-
Publication number: 20130224207Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: ApplicationFiled: October 18, 2011Publication date: August 29, 2013Applicants: Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Todd G. Smith, Xianfu Wu
-
Patent number: 8519108Abstract: The method of the present invention comprising successive column chromatography processes for the purification of an anthrax protective antigen can achieve an improved purity of the anthrax protective antigen product by effectively removing impurities (e.g., cellular residual proteins in the culture solution) without the loss of anthrax protective antigen. Therefore, the method of the present invention can be advantageously used for economically producing the anthrax protective antigen on a large scale.Type: GrantFiled: January 9, 2009Date of Patent: August 27, 2013Assignees: Korea Center For Disease Control and Prevention, Green Cross CorporationInventors: Hee-Bok Oh, Bong-Su Kim, Gi-Eun Rhie, Jeong-Hoon Chun, Hun Kim, SinKoo Yeo, MahnHoon Park, Chong-Hwan Jonathan Chang, Mi Sun Ahn
-
Patent number: 8512700Abstract: The invention provides an effective and environmentally friendly antibody protective agent and the methods of using it in immunological detection. The antibody protective agent helps antibody to maintain relatively high immunological activity at room temperature. Working electrodes coated with antibodies and the antibody protective agent are installed in immunological detection devices to enhance stability and accuracy of immunological detection. The antibody protective agent is effectively used in the detection of a variety of toxins, for example, aflatoxin, staphylococcal enterotoxin, algae toxin, and vomitoxin.Type: GrantFiled: July 31, 2010Date of Patent: August 20, 2013Assignees: Jiangnan University, Wuxi Center for Disease Control and PreventionInventors: Xiulan Sun, Yinzhi Zhang, Zaijun Li, Jingping Zhang, Weimin Niu
-
Publication number: 20130210010Abstract: Processes for the serotype specific detection and identification of one or more Salmonella serotypes are provided. A family of specific primers and probes are provided that allow screening of biological or environmental samples for robust, rapid, and reproducible detection and identification of one or more Salmonella serotypes in the sample.Type: ApplicationFiled: October 26, 2011Publication date: August 15, 2013Applicants: Department of Health & Human Services, Centers for Disease Control and PreventionInventors: Patricia Fields, John R. McQuiston, Collette Fitzgerald Leaumont
-
Publication number: 20130210031Abstract: One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample.Type: ApplicationFiled: November 8, 2011Publication date: August 15, 2013Applicant: CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Anne E. Boyer, Renato C. Lins, Zsuzsanna Kuklenyik, Maribel Gallegos-Candela, Conrad P. Quinn, John R. Barr
-
Publication number: 20130148117Abstract: Particles of a flow of aerosol are collected and analyzed by passing them through a housing having an inlet area, an outlet area, and a collection and analysis area interconnecting the inlet and outlet areas. A collection electrode has a tip disposed in the collection and analysis area and particles are collected thereon. After collection, the particles are ablated and atomic emissions are collected for analysis of the particles.Type: ApplicationFiled: December 9, 2011Publication date: June 13, 2013Applicants: Human Services, Centers for Disease Control and PreventionInventors: Pramod Kulkarni, Prasoon Diwakar
-
Publication number: 20130148252Abstract: A bipolar charger includes a housing with a main chamber and positive and negative electrode chambers facing each other. The electrode chambers each have a ground electrode and a high voltage electrode that cooperate to create a cloud of ions. An aerosol flowing from an inlet passage through the main chamber and out an outlet passage mixes with the clouds of ions, thereby providing an aerosol with a steady-state electric charge distribution.Type: ApplicationFiled: December 9, 2011Publication date: June 13, 2013Applicants: Human Services, Centers for Disease Control and PreventionInventors: Pramod Kulkarni, Chaolong Qi